Nabriva Announces Positive Topline RESULTS from LEAP 2

Driven to Deliver Innovative Treatments for Patients With Infectious Diseases

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics.
Learn More

PIPELINE &
RESEARCH

See Pipeline

PIPELINE & RESEARCH

Learn About Our Novel
Antibiotic Candidates

See Pipeline

FOR INVESTORS

Visit Investors Center

FOR INVESTORS

Find Shareholder News,
Events, & More

Visit Investors Center

CAREERS

View Jobs

CAREERS

Join Our Growing Team
at Nabriva

View Jobs

Collaborate With Us

We’re developing innovative therapies that have the potential to transform the lives of people with infectious diseases, and our current platform is just the beginning. We actively seek collaborators and licensing opportunities focused on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. Contact us to learn more.

Contact Us

In the News

10/25/17

Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference >

Read More View All
In the News

09/28/17

Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017 >

Read More View All
In the News

09/20/17

Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference >

Read More View All